Sophisticated investors are shying away from this one - even with a steep discount. I suspect they see that Ropren sales projections are hopelessly optimistic, and the lack of cash now has the manufacturing well behind schedule.
Even another round of director "buying" can't fool them. SLA desperately need an independent director to clean up their act.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.010(5.26%) |
Mkt cap ! $10.66M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.0¢ | $9.06K | 49.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31000 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 7422 | 1 |
View Market Depth
| Last trade - 14.41pm 19/09/2025 (20 minute delay) ? |
| SLA (ASX) Chart |